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The recent availability of the carcinoembryonic 
antigen (CEA) assay has stimulated great clinical in-
terest in tumor antigens. Carcinoembryonic antigen 
is not the only specific or tumor-associated antigen 
currently identified . There are a number of other 
tumor antigens which have been isolated, some of 
which are related to CEA and some of which are 
totally different. There is, for example, a nonspecific 
cross-reacting antigen (NCA) which has been discov-
ered in certain preparations which were considered 
originally to be CEA. Nonspecific cross-reacting 
antigen is a beta globulin (25% carbohydrate) which 
cross-reacts with antibodies to CEA and may be 
the nonspecific background element that causes the 
CEA titer to be elevated in certain nonmalignant 
diseases. There is also a membrane-associated, low 
molecular weight tissular autoantigen (MT A) which 
has been recently identified. However, this material 
is not antigenetically related to CEA or NCA. 
Carcinoembryonic antigen is an antigenetic 
glycoprotein. The antibody-active site of this antigen 
is actually in the glucose portion of the molecule 
rather than the protein portion. Carcinoembryonic 
antigen has a relatively high molecular weight 
(200,000) and is soluble in perchloric acid. The per-
chloric acid solubility of CEA has greatly facilitated 
extraction of the antigen from tumor tissue and is 
also responsible for the relative convenience of the 
current method of performing the radioimmuno-
assay for detection of this antigen. 
Carcinoembryonic antigen is present in the 
This is an edited transcription of a lecture presented by Dr. 
Hoffer at the Postgraduate Course in Nuclear Medicine, February 
27, 1975, in Williamsburg, Virginia. 
128 
glycocalyx of malignant gastrointestinal cells and is 
also present in fetal gastrointestinal tissues during the 
first and second trimesters of fetal life. Gold and 
Freedman discovered and isolated this material in 
1965 (I). A radioimmunoassay for its detection was 
developed soon after (2). Initial results with this assay 
indicated that elevated blood CEA level was a specific 
test for adenocarcinoma of the colon, although oc-
casional patients with pancreatic carcinoma also had 
elevated titers. However, more extensive clinical 
studies indicate that circulating CEA is not only pre-
sent in colonic and pancreatic malignancies but in 
other malignancies as well, as noted by H . J. Hansen, 
MD (oral communication, April , 1973). Unfor-
tunately, CEA is also present in certain nonmalignant 
disorders and some normal patients. the common 
denominator in most cases of elevated CEA level as-
sociated with bowel disease is rapid cellular prolifera-
tion with disruption of the basement membrane. The 
disruption of the basement membrane is important 
because the antigen must leak into the circulation in 
order to be detected. The cellular proliferation may 
be responsible for the cell surface exposure of certain 
primitive antigens that are not normally found in 
adult human tissues . The upper limit of normal for 
the currently available CEA assay is approximately 
2.5 ng/ ml. However, a finite percentage of normal in-
dividuals will have CEA levels above this value. 
Three percent of healthy, young nonsmoking 
volunteers and 19% of smokers have CEA levels over 
2.5 ng/ ml. There is some question as to whether the 
smokers who do have elevated titers are not in fact 
candidates for developing carcinoma of the lung, 
although the evidence for this is currently speculative. 
Former smokers have a fairly significant CEA titer 
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elevation. Thirty percent of patients with nonmalig-
nant disease may have a titer above 2.5 ng/ml, and 
10% of these patients have a titer above 5 ng/ml. 
However, the assay shows more frequent and more 
marked elevation of the antigen titer in patients with 
malignancy, especially colorectal carcinomas. Eighty 
percent of patients with colorectal carcinoma have a 
titer greater than 2.5 ng/ml. Fifty percent have a titer 
above 5 ng/ml. Other tumors such as lung carcinoma 
are also associated with a high incidence of elevated 
titer. 
An early criticism of the CEA assay was the high 
incidence of false-negative results in patients with 
early-stage colonic carcinomas. The five-year survival 
statistics for treated patients with Duke's stage A 
colonic carcinoma is almost 100%. In the stage B 
group, the survival is approximately 50% to 60%, and 
in the stage C group (those patients in whom the 
tumor has gone through the serosa and actually 
metastasized to local nodes), the survival drops to 
only about 25% at five years. Ideally, we would prefer 
an assay that would detect 100% of patients with 
colonic carcinoma, Duke's stage A (assuming that 
most of these tumors do go through a progression 
from stages A to C). However, using the current CEA 
assay, only 20% of patients with stage A lesions will 
have an elevated titer. In other words, 80% of the 
patients with this type of lesion will have a normal 
CEA titer. About 40% to 50% of patients with stage B 
lesions will have positive titers . It is only when the le-
sion actually breaks through the serosa and is involv-
ing local nodes that the probability of an elevated 
CEA titer approaches 90% to 100%. Therefore, the 
current CEA immunoassay cannot be used alone as a 
cancer-screening study. Its value in screening 
patients, however, should not be totally discounted 
since there is a significant five-year survival in treated 
patients even in the stage B and C categories. 
Doctor William McCartney, Mrs. Erika Lawrence, 
and I performed a study at the University of Chicago, 
comparing the relative value of the CEA titer to the 
conventional colon examination for the diagnosis of 
carcinoma of the colon (3). The study included almost 
1,000 patients who were referred for radiologic colon 
examination . Carcinoembryonic antigen titer above 3 
ng/ ml (a level we arbitrarily selected to divide the 
normal from abnormal groups) was detected in 15% 
of patients subsequently diagnosed as normal, or 
having inactive inflammatory bowel disease. There 
was a 30% incidence of elevated titers in patients who 
had cirrhosis and noncolonic malignancies. Less than 
10% of the patients with benign colonic polyps in this 
series had significant titer elevation. 
By comparison, the conventional radiologic colon 
examination was positive, that is, showed evidence 
for malignancy in only 10 out of 850 patients who 
were subsequently established not to have colonic 
malignancy. The colon examination was, therefore, 
much more specific for excluding the diagnosis of car-
cinoma of the colon in patients subsequently proven 
not to have colonic maiignancy. 
Forty-eight of the patients in this series were subse-
quently proven to have carcinoma of the colon, first 
diagnosed at the time of the study. The CEA titer was 
normal in 16 of these patients and was abnormal in 
only 67%, whereas the conventional radiologic colon 
examination was abnormal in 90% of these patients. 
The radiologic colon examination was, therefore, 
clearly superior to the CEA test for detection of new 
carcinomas of the colon. However, there were three 
patients with carcinoma of the colon in this study in 
whom the radiologic colon examination was original-
ly considered to be normal or show signs representing 
benign disease, who did have elevated CEA titers. 
The CEA titer was potentially helpful in these cases 
in raising the suspicion of colonic carcinoma. If the 
results of the two tests are combined, the accuracy of 
the diagnosis is 96%, which represents some improve-
ment over the radiologic colon examination alone. 
In active ulcerative colitis, the CEA level is fre-
quently elevated and the level itself is not a useful clue 
to detect early development of malignancy. The 
patients with quiescent bowel disease usually have 
normal titers. In a patient with quiescent bowel dis-
ease, a rising CEA titer should be treated with great 
suspicion for neoplasm. 
Although the radiologic colon examination is 
clearly superior for the initial diagnosis of colonic 
malignancy, the CEA titer is equally superior for the 
diagnosis of recurrence of colonic carcinoma. In our 
studies of patients with recurrent colonic carcinoma, 
only 2 of 15 patients with recurrence had a normal 
CEA titer. The barium enema indicated recurrence in 
only 3 of these 15 patients. The barium enema did 
detect the two cases of recurrence with normal CEA 
titers . Frequently, the recurrence of colonic car-
cinoma is not in the area of the primary tumor but 
rather in the liver or.elsewhere in the body. It is also 
very difficult to distinguish postoperative changes in 
the bowel from early recurrence of tumor on a con-
ventional radiologic colon examination. These fac-
tors probably account for the poor detection rate of 
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recurrence seen with the conventional radiologic 
colon examination. 
In summary, the CEA titer is not as sensitive as the 
radiologic colon examination for the diagnosis of 
primary carcinoma, but it is very useful in following 
patients for recurrent carcinoma. 
Another area of potential use for the CEA 
radioimmunoassay is in the detection of metastatic 
malignancy of noncolonic origin. The test is ex-
tremely useful when interpreted in conjunction with 
other tests for metastatic disease. Doctor William 
McCartney, Erika Lawrence, and I studied 368 
patients who had both liver scans and CEA im-
munoassay (4). The liver scan is a useful test for the 
detection of hepatic metastasis for many primary 
malignancies; however, it has a 30% incidence of false-
negative results and a 10% to 20% incidence of false-
positive results. The false-positive cases are primarily 
patients with other disorders such as cirrhosis, who 
show lesions on the liver scan which closely mimic 
metastatic tumor. In this study, we chose a level of 9 
ng/ ml as a dividing line between a positive result for 
metastatic tumor and negative evidence for 
metastatic tumor. It should be noted that this level is 
considerably higher than the level usually selected for 
detecting carcinoma of the colon. 
Neither the liver scan nor the CEA assay was 
perfect in detecting hepatic metastasis. However, 
when the results of both tests were positive, the 
probability that the patient had metastasis was 
almost I 00%, and when both tests were negative, the 
probability of hepatic metastasis dropped to I%. If 
the liver scan only was positive, the probability of 
metastasis dropped to 60%, and if the CEA titer only 
was positive, that is, above 9 ng/ ml, the probability 
of hepatic metastasis was only 30%. These results sug-
gest an important role of the CEA titer in evaluating 
the patients with many types of tumors other than 
colonic malignancy. 
The continuing clinical use of the CEA titer will 
undoubtedly reveal many other situations in which 
the study is valuable. It is certainly not a diagnostic 
panacea, and the results must be interpreted with 
considerable caution. However, I believe we can look 
forward to an era of continued expansion in this type 
of tumor radioimmunoassay. More specific assays for 
colonic tumor are being developed and will un-
doubtedly become available in the future. I am equal-
ly confident that similar assay techniques will be 
developed for other types of malignancies. 
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